drugset / Trial / NCT06889766
NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma
NaSingle-groupOpen-labelTreatment
Summary
A single center, dose escalaion, Phase I clinical trial to demonstrate safety and efficacy of LauT-1, autologous "New York Esophageal Squamous Cell Carcinoma-1 T-Cell Receptor (NY-ESO-1 TCR)-directed T cells in combination with non-myeloablative (NMA) lymphodepleting chemotherapy and low dose irradiation (LDI) in patients with NY-ESO-1 positive sarcoma and melanoma.
Timeline
- Start
- 2025-03-24
- Primary completion
- 2029-06
- Completion
- 2029-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LauT-1 | Cell therapy | 3e+08 cells | Intravenous |
| Subject | LauT-1 | Cell therapy | 6e+08 cells | Intravenous |
| Subject | LauT-1 | Cell therapy | 2e+09 cells | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 900 mg/m2 | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 1800 mg/m2 | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 2400 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |